Medicare and its patients were overbilled by $17 million in a national study of chemotherapy because the doctors doubled-billed, took payments without giving treatment and took payments for patients who didn’t have cancer, an internal review found.

The Inspector General of Health and Human Services report, released to the public Wednesday, found Medicare made payments in a chemotherapy “demonstration” for almost 44,000 patients who weren’t receiving chemotherapy.